eTable 6. The typical adverse effects of antipsychotics, according to the revised clinical practice guidelines (1).

	Akathisia	Parkinsonoid	Tardive dyskinesia	Weight gain	Metabolic changes	Diabetes mellitus	Obstipation	Hyperprolactinemia	Dysmenorrhea/ amenorrhea	Sexual dysfunction	Sedation	Orthostatic dysregulation	Prolongation of QT time	Increased transaminases/bilirubin	Blood count changes	Agranulocytosis/pancytopenia	Epileptic seizures	MNS	Pneumonia
Amisulpride	+	+	+	0/+	0/+	0/+	++	+++	++	++	0/+	0/+	++	0/+	0/+	0/+	0/+	?	0
Aripiprazole	++	+	+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	?
Cariprazine	++	++	+	0/+	0/+	0/+	0	0	0	0	0	0/+	0/+	++	0/+	0/+	0/+	0/+	?
Clozapine	+	0	0	+++	+++	+++	+++	0/+	0/+	+	+++	+++	+	++	+	++	++	0/+	++
Flupentixol	+++	+++	++	++	+	+	++	0/+	0/+	+	++	++	0/+	+	0/+	0/+	+	0/+	?
Fluphenazine	+++	+++	+++	0/+	0/+	0/+	+	0/+	0/+	+	++	++	+	+	+	0/+	++	0/+	?
Haloperidol	+++	+++	+++	+	0/+	0/+	+	+++	++	++	+	0	0/+	++	+	0/+	0/+	+	?
Lurasidone*	+/++	+/++	+	0/+	0/+	0/+	+	+	+	+	+	0/+	0/+	+	0/+	0/+	0/+	0/+	?
Melperone	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	0/+	++	++	+	0/+	+	0/+	?	0/+	?
Olanzapine	+	0/+	0/+	+++	+++	+++	++	+	0	+	+/++	++	0/+	+	0/+	0/+	0/+	0/+	+
Paliperidone	+	++	+	++	+	+	++	+++	+++	++	0/+	+	+	++	0/+	0/+	0/+	0/+	?
Perphenazine	++	++	++	++	+	?	+	+	+	+	+	+	+	0/+	0/+	0/+	0/+	0/+	?
Pipamperone	++	+	0/+	?	?	+	?	0/+	++	++	++	++	+	+	+	0/+	0/+	0/+	?
Quetiapine	+	0/+	0/+	++	++	++	+	0/+	0/+	+	++²	++²	+	++	++	0/+	0/+	0/+	+
Risperidone	+	++	+	++	+	+	++	+++	++	++	+	+	+	+	0/+	0/+	0/+	0/+	+
Sertindole	+	0/+	+	++	+	+	+	+	+	+	0/+	+	+++	0/+	0/+	0/+	0/+	0/+	?
Ziprasidone	+/++	+	+	0/+	0/+	0/+	0/+	+	0/+	+	+	0/+	++	+	0/+	0/+	0/+	?	?
Zuclopenthixol	+++	+++	++	++	+	+	++	++	++	++	+++	++	0/+	0/+	0/+	0/+	+	0/+	?

Adverse effects of antipsychotics (reproduced in full from the revised clinical practice guidelines (1). The table was compiled on the basis of the CINP Schizophrenia Guidelines and the references contained therein (e51) and on the previous AWMF guidelines on schizophrenia (39); adaptation took place in an expert consensus process based on product information sheets and recently published meta-analyses (28, 32). Gaps in the data were filled using the product information sheets and the standard reference for psychopharmacology in Germany (e49). The data on pneumonia were extracted from a meta-analysis (e34). Unexpected adverse effects may occur with widespread use of the preparations, so pharmacovigilance (seeeTable 5) is mandatory.

*Lurasidone is approved for the treatment of schizophrenia in Germany, but prescriptions for it cannot be charged to the National Association of Statutory Health Insurance Funds.

0 = None, (+) = sporadic or no significant difference from placebo, + = rare, ++ = occasional, +++ = frequent, ? = data insufficient for estimation of frequency. Please note that these are not systematically compiled quantitative estimates of incidence, but rather qualitative estimates based on clinical experience, taking account of the sources mentioned above. MNS, Malignant neuroleptic syndrome